x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor"s note: Episodes

health & fitness medicine

All Episodes

23:10

Orforglipron Availability, Amazon Pharmacy, and...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/04/16

The US Food and Drug Administration approval of orforglipron (Fondayo) in April 2026 may mark a pivotal shift in obesity care—particularly as the first oral GLP-1 option designed for flexible, real-world use. Within days, Eli Lilly and Company announced broad availability, including a same-day delivery partnership with Amazon Pharmacy, signaling a rapid move toward improved access following years of supply constraints affecting agents like tirzepatide.Watch on HCPLiveIn this episode of Diabetes

en-us

23:24

The G7 15-Day System and CGM Innovations at Dexcom,...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/04/06

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, host Diana Isaacs, PharmD, is joined by Jessica Castle, MD, vice president of medical affairs at Dexcom, to discuss the company’s recent innovations in continuous glucose monitoring (CGM) and their clinical implications.To open the episode, Castle outlines the launch of the Dexcom G7 15-day system, highlighting its extended wear duration, improved accuracy (MARD ~8%), and

en-us

12:31

FDA Approves Novo Nordisk’s Insulin Icodec-abae...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/04/04

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!On March 26, 2026, the US Food and Drug Administration (FDA) approved Novo Nordisk’s insulin icodec-abae under the name Awiqli for patients with type 2 diabetes (T2D).1,2In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlight the FDA approval of once-weekly insulin icodec, emphasizing its significance as a major advancement in insulin therapy. They begin by

en-us

36:18

2026 AACE Guidelines for Type 2 Diabetes

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/04/03

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!On March 17, 2026, the American Association of Clinical Endocrinology (AACE) released a consensus statement, which features an algorithm for the management of type 2 diabetes (T2D) in adult patients.1In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review the newly released 2026 American Association of Clinical Endocrinology (AACE) type 2 diabetes treatment

en-us

12:53

Orforglipron Receives FDA Approval for Chronic Weight...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/04/01

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!The US Food and Drug Administration (FDA) has approved orforglipron (Foundayo), a once-daily oral GLP-1 RA, for chronic weight management in adults with obesity or overweight and ≥1 weight-related comorbidity.1In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA’s decision and the myriad new treatment opportunities afforded by orforglipron’s clearance

en-us

34:38

Q1 2026 Updates from Tandem Diabetes Care, with...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/03/31

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Expanding access to and optimizing use of automated insulin delivery (AID) systems remains a central priority in diabetes care, with recent discussions highlighting practical strategies to improve outcomes across diverse patient populations.In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Laurel Messer, PhD, RN, vice president of medical affairs at

en-us

32:55

ATTD 2026 Recap

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/03/19

Advances in artificial intelligence, automated insulin delivery, and sensor integration were central to discussions at the 2026 International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), where clinicians highlighted how emerging technologies may further reduce diabetes management burden while improving glycemic outcomes.In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed key highlights from the meeting, with particular emphasis on AI-driven

en-us

26:41

Orforglipron, Retatrutide, and Other GLP-1 Updates

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/03/02

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a comprehensive update on the rapidly evolving landscape of incretin-based therapies, focusing on newly published and top-line clinical trial data across oral GLP-1 receptor agonists and emerging triple agonists.Key Episode Timestamps00:00:01 Intro00:00:22 Orforglipron in the ACHIEVE-3 trial00:03:30 Side effects from

en-us

11:05

Launch of the Zepbound KwikPen

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/02/23

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a detailed update on evolving incretin-based therapies, with a primary focus on a significant formulation change for tirzepatide.Key Episode Timestamps00:00:01 Intro00:00:11 Zepbound in the KwikPen00:01:25 Vials versus pens00:02:55 Environmental benefits00:03:53 Pen needles sold separately00:06:30 LillyDirect availability00:07:20

en-us

13:42

Implantable Insulin Pumps and Interoperability

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/02/21

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore advances in implantable diabetes technologies, focusing on a novel implantable insulin pump from Portal Diabetes that has received FDA Breakthrough Device designation.Key Timestamps00:00:01 Intro00:00:14 Implantable insulin pumps00:01:06 What is breakthrough status?00:03:00 How the pump works00:03:41 What makes it different from

en-us

11:59

Oral Ozempic and the Risks of Compounding Formulas

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/02/13

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore major updates in the evolving GLP-1 receptor agonist landscape, with a particular focus on oral semaglutide formulations, branding changes, and regulatory concerns surrounding compounded alternatives.Key Episode Timestamps00:00:01 Intro00:00:25 Oral Wegovy and oral Ozempic00:03:04 Why Rybelsus didn't work00:05:33 The importance

en-us

17:56

Tech Updates on Twiist, MiniMed Go, and More

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/01/16

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide an in-depth review of several notable developments in diabetes technology, focusing on innovations in insulin pump interoperability, automated insulin delivery algorithms, continuous glucose monitoring, and decision-support tools for people using multiple daily injections (MDI).Key Episode Timestamps00:00:01 Intro00:00:19 The

en-us

37:37

Reviewing the New US Dietary Guidelines with Susan...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/01/15

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Susan Weiner, MS, a nationally recognized dietitian and diabetes care and education specialist, for an in-depth discussion of the newly released US Dietary Guidelines and the inverted food pyramid. The conversation is framed for clinicians navigating nutrition counseling in diabetes and cardiometabolic care, with a focus on how

en-us

18:18

Therapeutic Updates from the ADA 2026 Standards of Care

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/24

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review key therapy-focused updates from the 2026 ADA Standards of Care, emphasizing areas they view as practice-changing. Key Episode Timestamps 00:00:01 Intro 00:00:29 Adding GLP-1 RAs to heart failure 00:02:45 GLP-1s in glycemic management 00:04:36 Time in range targets in glycemic management 00:08:10 ADA recommends GLP-1s for

en-us

18:45

Orforglipron, Cagrilintide, and the Libre Assist

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/23

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at the University Hospitals Diabetes and Metabolic Care Center, review major therapeutic and technology

en-us

27:35

2026 Technology Updates and American Diabetes...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/17

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss major diabetes technology updates alongside key technology-related changes in the 2026 American Diabetes Association Standards of

en-us

9:41

Reacting to Retatrutide and TRIUMPH-4 Topline Data

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/17

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, share early impressions of topline phase 3 results from the TRIUMPH-4 trial of retatrutide, a once-weekly triple agonist targeting GIP, GLP-1,

en-us

13:25

Semaglutide Falls Short in Alzheimer Disease,...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/11/25

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, breakdown recent trial news from the 2 most popular incretin therapies: semaglutide and tirzepatide. First, hosts breakdown the November 24, 2025 announcement from Novo Nordisk disclosing their evoke and evoke+ trials of oral semaglutide in early symptomatic Alzheimer Disease failed to slow disease progression. Next, hosts break down the TIRTLE study, which examined use of tirzepatide in patients with type 1

en-us

20:49

Updates on Dexcom G7 and Semaglutide Pricing

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/11/21

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review two major developments in diabetes care: the forthcoming 15-day Dexcom G7 continuous glucose monitor (CGM) and significant new price reductions for semaglutide as Ozempic and Wegovy.Key Episode Timestamps 00:00:01 Introduction 00:00:30 Dexcom G7 00:01:55 A 15-Day Sensor With a 12-Hour Grace Period 00:04:27 Seamless transition to the new G7 00:05:23 Looking back at Dexcom's advancements 00:06:34 Dexcom's Smart Basal

en-us

14:24

Oral Semaglutide and SELECT at DTM 2025

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/10/29

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide.Key Episode Timestamps 00:00:01 Introduction 00:00:42 Oral semaglutide's FDA approval 00:02:02 The SOUL trial and Rybelsus's cardiovascular indication 00:03:35 Dosing for Rybelsus 00:06:18 The SELECT trial 00:08:29 Can GLP-1s be cardiovascular treatments? 00:14:08 Outro

en-us

189 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown